Navigation Links
Satraplatin in Medical News

Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial

- Overall survival results do not achieve statistical significance - GPC Biotech schedules conference call for Wednesday, October 31st, 8:30 AM ET/13:30 CET BOULDER, Colo., MARTINSRIED, Germany, MUNICH, Germany and PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ ...

GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial

... announced that the Phase 3 SPARC trial evaluating satraplatin for the treatment of hormone-refractory prostate c...taxel, RenaZorb(TM), SPI-1620 and SPI-205." About satraplatin In 2002, Spectrum licensed the global rights to G...a Co., Ltd. Spectrum licensed worldwide rights to satraplatin from Johnson Matthey PLC. About Spectrum Pharmace...

Satraplatin Benefits Hormone Refractory Prostate Cancer Patients

...ort from Columbia University on Phase III trial on satraplatin has shown: * Highly Statistically Significant ... Chemotherapy Treatment, including Taxotere? * satraplatin was Well Tolerated with Myelosuppression the Most ..., all of which require intravenous administration, satraplatin is an orally bioavailable compound and is given as...
Satraplatin in Medical Technology

Additional Data From Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress

Patients treated with Satraplatin Demonstrated Statistically Significant Improvement in Pain Response and PSA Response Rates BERLIN, March 22, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation and GPC Biotech AG today announced additional data from the double-blind, randomized satraplatin Phase ...

Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association

-- Median time to pain progression is 66.1 weeks for the satraplatin arm compared with 22.3 weeks for the placebo arm -- Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representing a 36% reduction in the relative risk of pain progression MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-Fi...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

- All pre-specified subset analyses of progression-free survival in the SPARC Phase 3 trial consistently demonstrate a reduction in relative risk of disease progression for patients receiving satraplatin. These analyses included prior Taxotere use, geographies, as well as presence or absence of pai...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

-- All pre-specified subset analyses of progression-free survival in the SPARC Phase 3 trial consistently demonstrate a reduction in relative risk of disease progression for patients receiving satraplatin. These analyses included prior Taxotere use, geographies, as well as presence or absence of pa...

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

...istic Interaction between the Oral Platinum Analog satraplatin and Erlotinib In preclinical studies, satraplatin was active in a number of various tumor models and... lines to satraplatin was examined. Conclusion satraplatin is synergistic with erlotinib, which may be relate...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

...esented or published, including Phase III data for satraplatin and Thalidomide, encouraging Phase II data for Amr...pm; McCormick Place Convention Center, S Hall A2 satraplatin Oral Presentation: satraplatin demonstrates significant clinical benefits for the...
Satraplatin in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Cellular Immunotherapy II-59 Spectrum Announces Positive Outcome of satraplatin Trial on HRPC Patients II-59 Panacea Pharmaceuticals Identifies Blo...plera Corporation II-69 GPC Biotech and Celgene Terminate Agreement for satraplatin II-70 EUSA Acquires Cytogen Corporation II-70 Eisai Acquires MGI Ph...

Pharmion Corporation Announces 2007 Operating Results

...1, 2007 include a charge of $8 million for a milestone payment triggered by the acceptance of Pharmion's marketing authorization application (MAA) for satraplatin for the treatment of second-line hormone-refractory prostate cancer by the European Medicines Agency (EMEA). Research and development expenses total...

Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

...tudies; (2) that the Company continued to evaluate satraplatin using the disputed endpoint; (3) that the Company ... with the disputed primary endpoint supporting its satraplatin New Drug Application ("NDA"); (4) that the FDA's e...h the NDA would not allow the FDA to conclude that satraplatin was more effective than placebo in terms of overal...

Finkelstein Thompson LLP Announces GPC Biotech AG Investigation

...Complaint further alleges that, under increased pressure to gain FDA marketing approval, Defendants used improper testing methods to determine whether satraplatin was safe and effective. On July 24, 2007, the FDA disclosed that it had unanimously recommended against the approval of Satraplatin. The market respo...
Other Tags
(Date:7/11/2014)... Butler Mobility has recently updated the paint color choices ... Previously the two standard colors were beige and brown. ... as standard colors at no additional charge! These colors ... enhance the beauty of the stairway. Homeowners will find ... individual décor. , The new selection of standard colors is: ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... who was thought to be cured by immediate and aggressive ... of the AIDS-causing virus in her bloodstream, disappointed federal officials ... old, had remained virus-free even though she stopped taking HIV ... her remission would open the door to a functional cure ...
(Date:7/11/2014)... July 11, 2014 As part ... Bernstein Liebhard LLP has been closely monitoring the ... Administration’s (FDA) Obstetrics and Gynecology Devices Panel, ... mitigate the cancer risks associated with the use ... According to a report published by Dow Jones ...
(Date:7/11/2014)... 2014 Datalogic brings a new and ... hospital wide. With their new Gryphon GD4400 ... like the devastating MRSA, which claimed 5,500 lives, becomes ... 2D and the Gryphon GM4400-HC 2D readers can ... even read barcodes off of troublesome LCD monitors, smartphones, ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- In people with sex ... similar to that seen in drug addicts as they ... clear differences in brain activity between patients who have ... those of drug addicts," study author Dr. Valerie Voon, ... a university news release. Voon,s research involved 19 ...
Breaking Medicine News(10 mins):Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2
(Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... in eastern New South Wales, Australia when NASA,s Aqua ... UTC on July 11 (12:35 p.m. local time/11:35 p.m. ... New South Wales (NSW), the Moderate Resolution Imaging Spectroradiometer ... region and spotted smoke (light brown) from various fires. ... outlined in red. , The New South Wales, Australia ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
Other Contents